Session Speaker

Eli Lilly External Pharmaceutical Innovation Partnering Strategies
Yetunde Taiwo
USA

Eli Lilly and Company is a global pharmaceutical company with extensive capabilities and expertise in the development of small and large molecule (e.g., antibodies, proteins, peptides) therapeutics. Lilly's internal research concentrates mainly in the Diabetes and Oncology as well as Neuroscience, Musculoskeletal, Autoimmune and Cardiovascular therapeutic areas. While Lilly maintains a pipeline of high value innovative assets, partnering and collaborations remain key strategic growth imperatives.

At Eli Lilly, we are exploring novel partnership strategies across all stages of pharmaceutical research and development to identify innovative molecules, cutting edge technologies and partners with outstanding capabilities around the globe to bring innovative medicines that improve patient outcomes to market.

Eli Lilly's Global External Research and Development (GER&D) Organization leads the identification and assessment of potential partnering efforts with external institutions and companies and performs technical and scientific assessments and due diligences to enable potential partnerships. GER&D is composed of experienced pharmaceutical scientists and clinicians who proactively scout and evaluate scientific innovation around the world to identify differentiated "first-in-class" and "best-in-class" molecules and technologies that match strategic needs across all Eli Lilly and Company functions and portfolios. GER&D has a global orientation in the pursuit of external scientific innovation, with geographically located personnel and numerous successful partnerships all around the world. Dr. Yetunde Taiwo, who is responsible for Musculoskeletal and Auto-Immune Diseases, Inflammation, Technologies, Biomarkers and new disease areas outside Lilly's current Therapeutic areas within the GER&D organization, will provide insights into Lilly's evolving, innovative, partnership strategies.